Pfizer Rises on Q4 Earnings Beat, 2025 Outlook Reaffirmed

GuruFocus.com

02-04

Pfizer (NYSE:PFE) shares rose over 1% in pre-market trading Tuesday after the pharmaceutical giant beat Q4 earnings and revenue estimates while reaffirming its 2025 financial guidance.

Q4 Results

Non-GAAP EPS: $0.63 (beat by $0.17)
Revenue: $17.8 billion ( 24.9% YoY, beat by $540 million)
Key Growth Areas: Primary care and oncology revenue increased 27% YoY Top-Selling Drug: Eliquis (apixaban), co-marketed with Bristol-Myers Squibb (BMY), generated $1.8 billion in revenue (+14% YoY)
Biggest Revenue Gain: Vyndaqel and Vyndamax (tafamidis) sales grew 61% YoY to $1.5 billion

Warning! GuruFocus has detected 7 Warning Signs with PFE.

2025 Guidance & Cost Savings

Pfizer reaffirmed its 2025 financial guidance, projecting revenue between $61 billion and $64 billion (midpoint: $62.5 billion, slightly below the $63 billion consensus). Adjusted EPS is expected between $2.80 and $3.00 (midpoint: $2.90, just below the $2.93 consensus).

The company remains on track to achieve $4.5 billion in cost savings by year-end through its ongoing cost realignment program. CEO Albert Bourla stated that while 2024 focused on commercial effectiveness, 2025 will emphasize R&D productivity, alongside continued efforts on margin expansion, commercial excellence, and shareholder-friendly capital allocation.

This article first appeared on GuruFocus.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2508802468"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2508802468\",edition:\"fundamental\",,,undefined,":{"share":"https://ttm.financial/m/news/2508802468?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-02-04 22:56","share_image_url":"https://static.laohu8.com/5f26f4a48f9cb3e29be4d71d3ba8c038","id":"2508802468","market":"us","top_or_hot":-1,"title":"Pfizer Rises on Q4 Earnings Beat, 2025 Outlook Reaffirmed","media":"GuruFocus.com","content":"<html><body><p><span>Pfizer (NYSE:PFE) shares rose over 1% in pre-market trading Tuesday after the pharmaceutical giant beat Q4 earnings and revenue estimates while reaffirming its 2025 financial guidance. </span></p>\n<p><span><strong>Q4 Results</strong></span></p>\n<ul>\n<li><span>Non-GAAP EPS: $0.63 (beat by $0.17) </span></li>\n<li><span>Revenue: $17.8 billion (</span><span> 24.9% YoY, beat by $540 million</span><span>) </span></li>\n<li><span>Key Growth Areas: Primary care and oncology revenue increased 27% YoY Top-Selling Drug: Eliquis (apixaban), co-marketed with Bristol-Myers Squibb (BMY), generated $1.8 billion in revenue (+14% YoY) </span></li>\n<li><span>Biggest Revenue Gain: Vyndaqel and Vyndamax (tafamidis) </span><span>sales grew 61% YoY to $1.5 billion</span></li>\n</ul>\n<ul>\n<li>Warning! GuruFocus has detected 7 Warning Signs with PFE.</li>\n</ul>\n<p><span><strong>2025 Guidance & Cost Savings </strong></span></p>\n<p><span>Pfizer reaffirmed its 2025 financial guidance, projecting revenue between $61 billion and $64 billion (midpoint: $62.5 billion, slightly below the $63 billion consensus). Adjusted EPS is expected between $2.80 and $3.00 (midpoint: $2.90, just below the $2.93 consensus). </span></p>\n<p><span>The company remains on track to achieve $4.5 billion in cost savings by year-end through its ongoing cost realignment program. CEO Albert Bourla stated that while 2024 focused on commercial effectiveness, 2025 will emphasize R&D productivity, alongside continued efforts on margin expansion, commercial excellence, and shareholder-friendly capital allocation.</span></p>This article first appeared on \nGuruFocus.\n<br/></body></html>","source":"yahoofinance","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta content=\"text/html; charset=utf-8\" http-equiv=\"Content-Type\"/>\n<meta content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\" name=\"viewport\"/>\n<meta content=\"telephone=no,email=no,address=no\" name=\"format-detection\"/>\n<title>Pfizer Rises on Q4 Earnings Beat, 2025 Outlook Reaffirmed</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nPfizer Rises on Q4 Earnings Beat, 2025 Outlook Reaffirmed\n</h2>\n<h4 class=\"meta\">\n</h4><p class=\"head\">\n<strong class=\"h-name small\">GuruFocus.com</strong><span class=\"h-time small\">2025-02-04 22:56</span>\n</p>\n</header>\n<article>\n<p><span>Pfizer (NYSE:PFE) shares rose over 1% in pre-market trading Tuesday after the pharmaceutical giant beat Q4 earnings and revenue estimates while reaffirming its 2025 financial guidance. </span></p>\n<p><span><strong>Q4 Results</strong></span></p>\n<ul>\n<li><span>Non-GAAP EPS: $0.63 (beat by $0.17) </span></li>\n<li><span>Revenue: $17.8 billion (</span><span> 24.9% YoY, beat by $540 million</span><span>) </span></li>\n<li><span>Key Growth Areas: Primary care and oncology revenue increased 27% YoY Top-Selling Drug: Eliquis (apixaban), co-marketed with Bristol-Myers Squibb (BMY), generated $1.8 billion in revenue (+14% YoY) </span></li>\n<li><span>Biggest Revenue Gain: Vyndaqel and Vyndamax (tafamidis) </span><span>sales grew 61% YoY to $1.5 billion</span></li>\n</ul>\n<ul>\n<li>Warning! GuruFocus has detected 7 Warning Signs with PFE.</li>\n</ul>\n<p><span><strong>2025 Guidance & Cost Savings </strong></span></p>\n<p><span>Pfizer reaffirmed its 2025 financial guidance, projecting revenue between $61 billion and $64 billion (midpoint: $62.5 billion, slightly below the $63 billion consensus). Adjusted EPS is expected between $2.80 and $3.00 (midpoint: $2.90, just below the $2.93 consensus). </span></p>\n<p><span>The company remains on track to achieve $4.5 billion in cost savings by year-end through its ongoing cost realignment program. CEO Albert Bourla stated that while 2024 focused on commercial effectiveness, 2025 will emphasize R&D productivity, alongside continued efforts on margin expansion, commercial excellence, and shareholder-friendly capital allocation.</span></p>This article first appeared on \nGuruFocus.\n<br/>\n<div class=\"bt-text\">\n<p> 來源：<a href=\"https://finance.yahoo.com/news/pfizer-rises-q4-earnings-beat-145630513.html\">GuruFocus.com</a></p>\n<p>為提升您的閱讀體驗，我們對本頁面進行了排版優化</p>\n</div>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"PFE","symbol_name":"輝瑞","start_time":0,"source_url":"https://finance.yahoo.com/news/pfizer-rises-q4-earnings-beat-145630513.html","article_id":"2508802468","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2508802468","pubTimestamp":1738680990,"columns":[],"sourceInfo":{"source_id":"yahoofinance","name":"雅虎金融"},"weMediaInfo":null,"summary":"Pfizer  shares rose over 1% in pre-market trading Tuesday after the pharmaceutical giant beat Q4 earnings and revenue estimates while reaffirming its 2025 financial guidance.Key Growth Areas: Primary care and oncology revenue increased 27% YoY Top-Selling Drug: Eliquis , co-marketed with Bristol-Myers Squibb , generated $1.8 billion in revenue . Biggest Revenue Gain: Vyndaqel and Vyndamax  sales grew 61% YoY to $1.5 billion. GuruFocus has detected 7 Warning Signs with PFE.Pfizer reaffirmed its 2025 financial guidance, projecting revenue between $61 billion and $64 billion . Adjusted EPS is expected between $2.80 and $3.00 .The company remains on track to achieve $4.5 billion in cost savings by year-end through its ongoing cost realignment program. CEO Albert Bourla stated that while 2024 focused on commercial effectiveness, 2025 will emphasize R&D productivity, alongside continued efforts on margin expansion, commercial excellence, and shareholder-friendly capital allocation.This artic","collect":0,"end_time":0,"defaultTopTitle":"yahoo.com","property":["earning"],"viewcount":null,"language":"en","relate_stocks":{"PFE":"辉瑞"},"translate_title":"辉瑞第四季度盈利超出预期，2025年前景得到重申","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"PFE":1},"content_text":"Pfizer (NYSE:PFE) shares rose over 1% in pre-market trading Tuesday after the pharmaceutical giant beat Q4 earnings and revenue estimates while reaffirming its 2025 financial guidance. \nQ4 Results\n\nNon-GAAP EPS: $0.63 (beat by $0.17) \nRevenue: $17.8 billion ( 24.9% YoY, beat by $540 million) \nKey Growth Areas: Primary care and oncology revenue increased 27% YoY Top-Selling Drug: Eliquis (apixaban), co-marketed with Bristol-Myers Squibb (BMY), generated $1.8 billion in revenue (+14% YoY) \nBiggest Revenue Gain: Vyndaqel and Vyndamax (tafamidis) sales grew 61% YoY to $1.5 billion\n\n\nWarning! GuruFocus has detected 7 Warning Signs with PFE.\n\n2025 Guidance & Cost Savings \nPfizer reaffirmed its 2025 financial guidance, projecting revenue between $61 billion and $64 billion (midpoint: $62.5 billion, slightly below the $63 billion consensus). Adjusted EPS is expected between $2.80 and $3.00 (midpoint: $2.90, just below the $2.93 consensus). \nThe company remains on track to achieve $4.5 billion in cost savings by year-end through its ongoing cost realignment program. CEO Albert Bourla stated that while 2024 focused on commercial effectiveness, 2025 will emphasize R&D productivity, alongside continued efforts on margin expansion, commercial excellence, and shareholder-friendly capital allocation.This article first appeared on \nGuruFocus.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0}}}